MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

George Evans had the opportunity of a lifetime as he stepped up to the mound to throw the first pitch at the Athletics game against the Houston Astros ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced ...

Engaging in leisure-time moderate- to vigorous-intensity physical activity (MVPA) is associated with better overall survival for participants with a history of various cancers.

AMPLITUDE is the “first trial to show efficacy for the combination of inhibition of PARP and the androgen receptor pathway in metastatic, castration-sensitive prostate cancer with alteration of genes ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

The University of Liverpool is leading a major €8.6m (£7m) EU-funded research project to tackle a growing medical challenge ...

As a correspondent for the Atlantic, Vanity Fair and the New York Times, he wrote vivid accounts of aviation disasters, shipwrecks and the Iraq War.

Standing at just 5 feet 1 inch tall, Carol Johnson-Cromer is a force of nature, radiating energy, resilience, and an ...